Healthcare

March 12, 2020

1

Patient Safety Movement Foundation Appoints New Chairman; Announces Drive Toward Zero Preventable Patient Deaths By 2030

Patient Safety Movement Foundation (PSMF) – a global non-profit dedicated to unifying those involved in the healthcare ecosystem, identifying challenges that are causing patient deaths, and creating actionable solutions to mitigate them – is pleased to announce the appointment of its new chairman of the board of directors – Michael A.E. Ramsay, MD, FRCA. It also reaffirms its commitment to patient health and safety with updates to its mission, vision and values; and reestablishes its goal of achieving ZERO preventable patient deaths by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200310005733/en/ As one of PSMF’s longest-standing board members, serving since 2013, Dr. Ramsay has been an advocate for patient safety in the anesthesia world since the 1980’s and embodies the values and principles......

Continue Reading >

March 12, 2020

2

M-learning app to strengthen health workforce training launched in Kenya

A new mobile App to facilitate and advance digital training of health workers in Africa has been launched by Amref Health Africa’s Institute of Capacity Development (ICD) in collaboration with the Elsevier and Dioraphte Foundations.

The Jibu mobile learning solution allows for self-paced, self-administered learning and is aimed at improving the skills and knowledge of health workers in sub-Saharan Africa. The App, which targets both pre-service"...

Continue Reading >

March 12, 2020

3

Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance

Regulatory News:

Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The company exceeded its raised guidance for full-year 2019 on both net sales and EBITDA.

FINANCIAL PERFORMANCE: STRONG SALES AND PROFIT GROWTH CONTINUES

March 11, 2020

4

Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO™ (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients. The addition of ixazomib to lenalidomide and dexamethasone resulted in an improvement in median progression-free survival (PFS) of 13.5 months (35.3 months versus 21.8 months; hazard ratio [HR] 0.83; p=0.073); however, it did not meet the threshold for statistical significance. The safety profile associated with NINLARO from the TOURMALINE-MM2 trial was generally consistent with the existing prescribing information. Results from the TOURMALINE-MM2 study will be submitted to an upcoming medical congress. “There is a need for treatment options in transplant ineligible patients. We remain......

Continue Reading >

March 11, 2020

5

Sinterex named Best 3D-Printed Healthcare Products Manufacturer Middle East

Global Health & Pharma (GHP), a global information sharing platform & a multi-disciplinary members community announced winners of the 2019 Technology Awards this month and recognised Sinterex as Best 3D-Printed Healthcare Products Manufacturer – Middle East.

In its announcement, GHP said, “Technology is a great force for change across numerous industries, sectors and fields. In the global healthcare industry, it has become a"...

Continue Reading >

March 9, 2020

6

Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today will share with members of the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with COVID-19, while also studying whether Takeda’s currently marketed and pipeline products may be effective treatments for infected patients. SARS-CoV-2 is the virus that causes COVID-19. Hyperimmune globulins are plasma derived-therapies that have previously been shown to be effective in the treatment of severe acute viral respiratory infections and may be a treatment option for COVID-19. As a leader in plasma-derived therapies with more than 75 years of experience in the development of plasma-derived products, Takeda has the expertise to research, develop, and manufacture a potential anti-SARS-CoV-2 polyclonal......

Continue Reading >

March 8, 2020

7

Egg Freezing Techniques Offering Women Flexibility on Their Motherhood Timeline Become Increasingly Popular

In observance of International Women’s Day, Fakih IVF Fertility Center is rolling out a special campaign supporting all women and their choices. The campaign is running throughout March, across the center’s branches located in Abu Dhabi, Dubai and Al Ain.

With majority of women considering delaying pregnancy or choosing to embrace motherhood later in their lives, the various methods of fertility preservation available today give them"...

Continue Reading >

March 7, 2020

8

Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer

– If Approved by the European Medicines Agency, ALUNBRIG Would Become an Important First-Line Treatment Option for ALK+ NSCLC Patients –

– Positive Opinion is Based on Data from Phase 3 ALTA-1L Trial, in which ALUNBRIG Demonstrated Superiority in both Overall and Intracranial Efficacy Compared to Crizotinib –

Takeda Pharmaceutical Company Limited"...

Continue Reading >

March 6, 2020

9

Takeda Completes Sale of Select OTC and Non-Core Assets to Acino

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa countries within its Growth and Emerging Markets Business Unit (GEM BU) to Acino for a total value in excess of $200 million USD. The divestment agreement was first announced in October 2019. The transaction includes approximately 30 select prescription pharmaceutical and OTC products. These products will continue to be made available by Takeda in other parts of the world. Close to 270 employees, primarily sales and marketing professionals supporting the portfolio, are also transitioning to Acino. The parties also entered into multi-year manufacturing and supply agreements, under which Takeda will continue to manufacture......

Continue Reading >

March 6, 2020

10

Dahua Thermal Solution Supports Epidemic Prevention and Control

The year 2020 is bound to be a special year with the outbreak of coronavirus disease 2019 (COVID-19) globally. Until today, the highly contagious disease has taken away many lives, especially in China, South Korea, Japan, and some countries in Europe and Middle East.

Dahua Technology, a world-leading video-centric smart IoT solution and service provider, has been an early participant in the epidemic prevention and control in Asia, joining the global"...

Continue Reading >


Forex News Headline



Forex Market Video